Teva lawsuit over generics of Lilly's Forteo brought back by appeals court
Seeking Alpha ·
A federal appeals court on Monday revived a lawsuit brought by Teva Pharmaceutical Industries ( TEVA ) against Eli Lilly ( LLY ) over an agreement that allowed the former to market a generic version of the latter's osteoporosis drug Forteo (teriparatide).
AI 시장 분석
TEVA is facing a retrial over a contract with Eli Lilly regarding genericization of a product.
상승 영향
- Pharmaceuticals — If TEVA's retrial of the Forteo genericization contract goes in their favor, it could lead to a decrease in Eli Lilly's product sales and revenue.
하락 영향
- Pharmaceuticals — If TEVA's retrial of the Forteo genericization contract doesn't go in their favor, it could lead to an increase in generic versions of Eli Lilly's product, potentially decreasing their sales and revenue.
DYAX 전담 분석
The retrial is related to the contract that allowed TEVA to sell a generic version of Eli Lilly's strong product Forteo.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 41% · Bearish (Short) 59%
454 participants
Related News
- 코스피 6763.53로 약세 지속...외국인·기관 순매수에도 낙폭 확대
- 삼성전자, 2Q 글로벌 스마트폰 점유율 24%…애플 제치고 1위 탈환
- 로킷헬스케어, ’세계 첫 신장재생 임상’ 본격화에 20% 가까이 급등
- The whole chip trade is waiting on one report
- Jim Cramer Calls Apple’s OpenAI Lawsuit “Heavyweight.” Tim Cook Must Believe OpenAI Was Stealing
- Netflix (NFLX) Secures Exclusive MLB Home Run Derby Streaming Rights